{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:49:59Z","timestamp":1791467399481,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.resmer.2026.101325","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:24:33Z","timestamp":1789226673000},"page":"101325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk factors and incidence of pneumonitis in NSCLC patient treated with chemoradiotherapy and Durvalumab: A comparative analysis with a non-Durvalumab cohort (PraDa)"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8307-4485","authenticated-orcid":false,"given":"Julien","family":"Swiderski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Evin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Durand-Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Duroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Lanoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Aziez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oulimata","family":"Dieng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Andraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Guillerm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Canellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Abbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gounant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Giroux-Leprieur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Chassagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Durdux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resmer.2026.101325_bib0001","unstructured":"Lap\u00f4tre-Ledoux B. Incidence des principaux cancers en France m\u00e9tropolitaine en 2023 et tendances depuis 1990 \/main Cancers INCIDENCE in Metropolitan France in 2023 and trends since 1990 2022."},{"issue":"11","key":"10.1016\/j.resmer.2026.101325_bib0002","doi-asserted-by":"crossref","first-page":"2744\u201153","DOI":"10.1002\/1097-0142(19800601)45:11<2744::AID-CNCR2820451108>3.0.CO;2-U","article-title":"A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the radiation therapy oncology group","volume":"45","author":"Perez","year":"1980","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0003","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received Durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"20","key":"10.1016\/j.resmer.2026.101325_bib0004","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013Small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.resmer.2026.101325_bib0005","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013Small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0006","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2004.02.015","article-title":"Prediction of radiation pneumonitis by dose\u2013volume histogram parameters in lung cancer\u2014A systematic review","volume":"71","author":"Rodrigues","year":"2004","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.resmer.2026.101325_bib0007","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung cancer","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.resmer.2026.101325_bib0008","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor\u2013Related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0360-3016(99)00183-2","article-title":"Clinical dose\u2013volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)","volume":"45","author":"Graham","year":"1999","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"5","key":"10.1016\/j.resmer.2026.101325_bib0011","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.ijrobp.2021.07.1691","article-title":"Predictors of pneumonitis after conventionally fractionated radiotherapy for locally advanced lung cancer","volume":"111","author":"McFarlane","year":"2021","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0012","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijrobp.2012.04.043","article-title":"Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis","volume":"85","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"7","key":"10.1016\/j.resmer.2026.101325_bib0013","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/JTO.0000000000000187","article-title":"Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non\u2013Small-cell lung cancer","volume":"9","author":"Tsujino","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.resmer.2026.101325_bib0014","first-page":"94\u2011102","article-title":"Initial evaluation of treatment-related pneumonitis in advanced-stage non\u2013Small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy","volume":"68","author":"Yom","year":"2007","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"1","key":"10.1016\/j.resmer.2026.101325_bib0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijrobp.2017.04.025","article-title":"Heart dosimetry is correlated with risk of radiation pneumonitis after lung-sparing hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma","volume":"99","author":"Yorke","year":"2017","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.resmer.2026.101325_bib0016","doi-asserted-by":"crossref","first-page":"58\u201164","DOI":"10.1016\/j.lungcan.2022.06.003","article-title":"Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab","volume":"170","author":"Gao","year":"2022","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.resmer.2026.101325_bib0017","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non\u2013Small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0018","doi-asserted-by":"crossref","first-page":"278\u201188","DOI":"10.1016\/j.jtho.2020.10.129","volume":"16","author":"Peters","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.resmer.2026.101325_bib0019","doi-asserted-by":"crossref","first-page":"39\u201151","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.resmer.2026.101325_bib0021","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). 2017."},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0022","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jtho.2019.10.024","article-title":"Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC","volume":"15","author":"Lin","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resmer.2026.101325_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110147","article-title":"Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer","volume":"194","author":"Smesseim","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.resmer.2026.101325_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111489","article-title":"Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer","volume":"128","author":"Peiliang Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.resmer.2026.101325_bib0025","article-title":"Symptomatic pneumonitis with Durvalumab after concurrent chemoradiotherapy in unresectable stage III NSCLC","volume":"5","author":"Vansteenkiste","year":"2024","journal-title":"JTO Clin Res Rep"},{"issue":"5","key":"10.1016\/j.resmer.2026.101325_bib0026","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ijrobp.2023.08.039","article-title":"Pneumonitis rates before and after adoption of immunotherapy consolidation in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation","volume":"118","author":"Yegya-Raman","year":"2024","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0027","article-title":"Predictors of pneumonitis in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiation followed by consolidative Durvalumab","volume":"8","author":"Diamond","year":"2023","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"10.1016\/j.resmer.2026.101325_bib0028","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.canrad.2012.03.003","article-title":"Cancers bronchiques non \u00e0 petites cellules : facteurs pr\u00e9dictifs de survenue de pneumopathie radique","volume":"16","author":"Giroux Leprieur","year":"2012","journal-title":"Cancer\/Radioth\u00e9rapie"},{"issue":"22","key":"10.1016\/j.resmer.2026.101325_bib0029","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1001\/archinternmed.2008.513","article-title":"Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses","volume":"168","author":"Engler","year":"2008","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.resmer.2026.101325_bib0030","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0031","article-title":"SeXX matters in infectious disease pathogenesis","volume":"12","author":"Vom Steeg","year":"2016","journal-title":"Heitman J, \u00c9diteur PLoS Pathog"},{"issue":"3","key":"10.1016\/j.resmer.2026.101325_bib0032","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"issue":"8","key":"10.1016\/j.resmer.2026.101325_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102590","article-title":"Immune checkpoint inhibitors-induced autoimmunity: the impact of gender","volume":"19","author":"Triggianese","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"13","key":"10.1016\/j.resmer.2026.101325_bib0034","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"JCO"},{"issue":"10","key":"10.1016\/j.resmer.2026.101325_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.08.573","article-title":"P1.01-17 Immune-related adverse events in patients with metastatic non-small cell lung cancer: sex differences and response to therapy","volume":"13","author":"Duma","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resmer.2026.101325_bib0036","doi-asserted-by":"crossref","first-page":"S1223","DOI":"10.1016\/j.annonc.2021.08.1737","article-title":"1795P Gender difference in side effects of immunotherapy: a possible clue to optimize cancer treatment","volume":"32","author":"Miceli","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.resmer.2026.101325_bib0037","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.3390\/cancers15072101","article-title":"The role of the gut microbiome in cancer immunotherapy: current knowledge and future directions","volume":"15","author":"Kiousi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.resmer.2026.101325_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2021.100912","article-title":"How biological sex of the host shapes its gut microbiota","volume":"61","author":"Valeri","year":"2021","journal-title":"Front Neuroendocr"},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0039","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/jnr.20881","article-title":"Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of treg cells, and enhanced expression of the PD-1 costimulatory pathway","volume":"84","author":"Polanczyk","year":"2006","journal-title":"J Neurosci Res"},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.radonc.2004.02.005","article-title":"A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis","volume":"71","author":"Claude","year":"2004","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1016\/j.resmer.2026.101325_bib0041","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO.1995.13.10.2606","article-title":"Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors","volume":"13","author":"Roach","year":"1995","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.resmer.2026.101325_bib0042","doi-asserted-by":"crossref","first-page":"187\u201199","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.resmer.2026.101325_bib0043","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3109\/0284186X.2013.831185","article-title":"Is there an impact of heart exposure on the incidence of radiation pneumonitis? Analysis of data from a large clinical cohort","volume":"53","author":"Tucker","year":"2014","journal-title":"Acta Oncol"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041226000796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041226000796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:51:47Z","timestamp":1791463907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041226000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":43,"alternative-id":["S2590041226000796"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2026.101325","relation":{},"ISSN":["2590-0412"],"issn-type":[{"value":"2590-0412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors and incidence of pneumonitis in NSCLC patient treated with chemoradiotherapy and Durvalumab: A comparative analysis with a non-Durvalumab cohort (PraDa)","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2026.101325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101325"}}